Optimization of a Behavioral Intervention to Increase Physical Activity in Older Adults Living With HIV
NCT05752500
Recruiting
The goal of this clinical trial is to examine 3 interventions designed to increase physical activity in older adults with HIV. We will examine 3 potential components of an intervention package: physical activity coaching, cognitive behavioral therapy targeted toward common barriers to physical activity such as low motivation or chronic pain, and a Fitbit-based social support intervention. Our primary outcome will be physical activity, defined as steps per day. Results will guide choice of interv... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/11/2025
Locations: Hennepin Healthcare Research Institute, Minneapolis, Minnesota +1 locations
Conditions: Hiv, Physical Inactivity, Aging
Register for Updates
Oropharyngeal Candidiasis (OPC) and S-ECC
NCT05761197
Recruiting
The overall objective of this study is to investigate the association of early Candida infection (known as oral thrush or oropharyngeal candidiasis, OPC) in children during the first year of life with the onset and severity of severe early childhood caries (S-ECC).
Gender:
ALL
Ages:
Between 9 months and 24 months
Trial Updated:
07/11/2025
Locations: Temple University, Philadelphia, Pennsylvania
Conditions: Candida Infection, Oral Thrush, Early Childhood Caries
Register for Updates
Disentangling the Role of Depression in Hypersomnia
NCT05850676
Recruiting
Individuals who have disorders of hypersomnolence (excessive sleepiness) often report symptoms of depression. The goal of this study is to further understand of the relationship between depression and hypersomnia by examining mood-relevant domains of slow wave sleep and reward function.
Gender:
ALL
Ages:
Between 21 years and 55 years
Trial Updated:
07/11/2025
Locations: The University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Hypersomnia
Register for Updates
Cord Blood Transplant in Adults With Blood Cancers
NCT05884333
Recruiting
Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the conditioning treatment (standard chemotherapy and total body irradiation therapy) given to prepare the body for transplant, the amount of stem cells transplanted, and how patients are followed during and after transplant.The purpose of this study is... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
07/11/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndromes (MDS), Myeloproliferative Disorder, Non-Hodgkin's Lymphoma
Register for Updates
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06001788
Recruiting
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +40 locations
Conditions: AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
Register for Updates
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06058013
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/11/2025
Locations: Neumora Investigator Site, Encino, California +70 locations
Conditions: Major Depressive Disorder
Register for Updates
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
NCT06058039
Recruiting
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and mee... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/11/2025
Locations: Neumora Investigator Site, Cerritos, California +68 locations
Conditions: Major Depressive Disorder
Register for Updates
An Organoid-based Functional Precision Medicine Trial in Osteosarcoma
NCT06064682
Recruiting
The purpose of this study is to examine if we can predict sensitivity of osteosarcoma to different chemotherapy agents using tissue cultures in the laboratory. We know that different chemotherapy agents can be used in the treatment, but not every sarcoma responds to them equally. It is important to understand if testing of the tissue obtained during a routine biopsy or surgery may be useful in selecting appropriate treatments. In addition, additional testing of the tumor, including genetic testi... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/11/2025
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Osteosarcoma
Register for Updates
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
NCT06067269
Recruiting
This phase II trial evaluates apalutamide in combination with image-guided stereotactic body radiation therapy (SBRT) for the treatment of patients with prostate cancer. Prostate cancer usually needs the hormone testosterone to grow. Apalutamide is a hormone therapy that blocks the effect of testosterone on prostate tumor cells. This may help stop the growth of tumor cells that need testosterone to grow. Image-guided SBRT is a standard treatment for some types of prostate cancer. This treatment... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Conditions: Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8
Register for Updates
Impact of Family-Centered Care for Intimate Partner Violence (IPV)
NCT06071299
Recruiting
The purpose of the study will be to determine how participation in Family-Centered Care (FCC) compared to Child-centered care (CCC) will affect caregiver engagement in IPV-based community services, caregiver perceptions of empowerment and survivor-defined practice, and clinical outcomes for children exposed to IPV.
Gender:
ALL
Ages:
All
Trial Updated:
07/11/2025
Locations: SCAN Clinic, Hartford, Connecticut +1 locations
Conditions: Intimate Partner Violence
Register for Updates
Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease
NCT06071429
Recruiting
The objective of this prospective, single-blinded, randomized controlled trial is to evaluate the safety and efficacy of the MAGNITUDE BRS System for the planned treatment of narrowed infrapopliteal lesions. Approximately 276 subjects will be randomized in a 1:1 ratio. The clinical investigation will be conducted at up to 60 clinical sites globally.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: NYU Langone Health, New York, New York +1 locations
Conditions: Chronic Limb-Threatening Ischemia
Register for Updates
Safety and Efficacy of the VERTICA® RF Device for the Treatment of ED
NCT06167733
Recruiting
Adult subjects with mild to moderate and moderate ED who meet the study eligibility criteria will be enrolled in the study. The enrolled subjects will be randomized by a 1:1 ratio to receive the Active or Sham VERTICA® treatment. Baseline assessments will include collection of demographic data, medical history, concomitant medications and baseline clinical examinations. The initial treatment session will be performed in a clinical setting simulating home use to determine proper device use and to... Read More
Gender:
MALE
Ages:
Between 22 years and 85 years
Trial Updated:
07/11/2025
Locations: University of California, Irvine Medical Center, Newport Beach, California +6 locations
Conditions: Erectile Dysfunction
Register for Updates